Sofosbuvir
(brand name Sovaldi) is a new drug used to treat hepatitis C. It was approved in Europe in January 2014 for the treatment of adults with all genotypes of chronic hepatitis C. For some people, sofosbuvir will be the first interferon-free drug. treatment option. Others believe that sofosbuvir can significantly shorten treatment time when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C, such as liver cancer or the need for a liver transplant. Sofosbuvir is one of the new direct-acting antiviral drugs targeting different stages of the hepatitis C virus (HCV) life cycle. It is a nucleotide analogue of an HCV polymerase inhibitor, which means it blocks the polymerase enzyme that the virus must use to reproduce. Sofosbuvir should be combined with other medications, which may include pegylated interferon (which stimulates the body's own immune response), ribavirin, or other direct-acting antivirals that work differently. Sofosbuvir is indicated for use in adults with chronic hepatitis C, which means an infection that lasts more than six months. It is approved for people with HCV genotype 1, 2, 3, 4, 5, or 6. Genotype 1 is the most common type in Europe and is considered the most difficult to treat. Sofosbuvir can be used by people new to treatment for hepatitis C (called "untreated") and to re-treat people who have not been cured by previous interferon therapy (known as "treated"). Sofosbuvir has also been tested in humans with HIV / HCV co-infection. Response rates and side effects are similar to those in HIV-negative people, and sofosbuvir does not interact with HIV drugs. Co-infected people who want to take sofosbuvir should do so under the supervision of a doctor who has experience in treating both infections.
Ledipasvir
//
Daclatasvir
//
Myhep Dvir
//
Velpatasvir
Sofosbuvir can be used by people with all stages of liver disease, including compensated and decompensated cirrhosis. However, it works better for people with less severe liver damage. Safety and efficacy data for decompensated liver cirrhosis have not yet been published. People with chronic hepatitis C who are awaiting liver transplants or who have received liver transplants tolerate sofosbuvir better than older medications.
|
Prihlásiť
Registrácia
English
